

AHPWA23AUSA

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1(Canceled).

2(Currently Amended). The method according to claim 3228, further comprising delivering an estrogen in combination with the compound of formula I.

3(Previously Presented). The method according to claim 2, wherein the estrogen is delivered prior to or subsequent to the compound of formula I.

4-7(Canceled).

8(Withdrawn and Currently Amended). The method according to Claim 3228, wherein said compound is selected from the group consisting of 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile, 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

9(Currently Amended). The method according to claim 3228, wherein said compound is 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

AHPWA23AUSA

10(Withdrawn and Currently Amended). The method according to claim 3228, wherein R<sup>1</sup> and R<sup>2</sup> are fused to form a carbon-based 3 to 6 membered saturated spirocyclic ring.

11-28(Canceled).


29(Currently Amended). The method according to claim 3228, wherein said compound is 5-(4-ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(4,4-diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-6-yl]-1H-pyrrole-2-carbonitrile, a tautomer, prodrug, metabolite, or pharmaceutically acceptable salts thereof.

30(New). The method according to claim 9, wherein said prodrug is an ester or carbamate.

31(Currently Amended). The method according to claim 3228, wherein said prodrug is an ester or carbamate.

32(New). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula I and a physiologically compatible carrier, wherein said compound of formula I is of the structure:

AHPWA23AUSA



I

wherein:

R<sup>1</sup> and R<sup>2</sup> are independent substituents selected from the group consisting of H, C<sub>1</sub> to C<sub>6</sub> alkyl, and substituted C<sub>1</sub> to C<sub>6</sub> alkyl; or

R<sup>1</sup> and R<sup>2</sup> are fused to form a carbon-based 3 to 8 membered saturated spirocyclic ring;

R<sup>3</sup> is H;

R<sup>4</sup> is H;

R<sup>5</sup> is a five membered carbon-based heterocyclic ring having in its backbone 1, 2, or 3 NR<sup>6</sup> heteroatoms and having one or two independent substituents selected from the group consisting of H, halogen, and CN;

R<sup>6</sup> is selected from the group consisting of H, C<sub>1</sub> to C<sub>3</sub> alkyl, and C<sub>1</sub> to C<sub>4</sub> CO<sub>2</sub>alkyl;

Q<sup>1</sup> is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.